Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis.

ABSTRACT:

Background

Biomarkers of rheumatoid arthritis (RA) disease activity typically measure inflammation or autoimmunity (e.g. CRP, RF). C1M and C3M, metabolites of type I and III collagen, are markers reflecting tissue metabolism. These markers have been documented to provide additional prognostic and predictive value compared to commonly used biomarkers. We investigated the relationship of high serum levels of C1M or C3M to radiographic progression, and benchmarked them to CRP and RF.

Methods

Placebo treated patients of the OSK1, 2 and 3 studies (Phase III clinical trials testing efficacy of fostamatinib) with baseline serum biomarkers C1M, C3M, CRP and RF were included (n_BL = 474). Van der Heijde mTSS was calculated at baseline and 24-week (n₂₄ = 261). Pro

SUBMITTER: Bay-Jensen AC 

PROVIDER: S-EPMC6390574 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature